Institute of Genetics and Cancer

Institute of Genetics and Cancer Translation and Commercialisation Board (TCB)

Driving translation of Institute of Genetics and Cancer science.

The Institute of Genetics and Cancer TCB is responsible for the development, implementation and monitoring of the strategy for efficient translation of the Institutes science and, where opportunities arise, to develop and commercialise innovative technologies to support future impact in medicine. We are comprised of Institute of Genetics and Cancer researchers with diverse clinical, drug and biologics discovery and development expertise.

Enquiries relating to the Institutes translation, partnerships and commercialisation should be addressed to:

Andrea Taylor,  Business Development Manager, Edinburgh Innovations

Board Members

IGMM Translation and Commercialisation Board (TCB)
Tim Aitman, Chris Boyd, Neil Carragher (Chair), Helen Colhoun, David FitzPatrick, Liz Patton, Andrew McBride, Andrea Taylor, Asier Unciti-Broceta, Helen Nickerson

Tim Aitman

  • Genomic medicine
  • Molecular pathology
  • Cell free DNA approaches

Chris Boyd

  • 15 years' experience of translational research in the field of cystic fibrosis gene therapy
  • Senior member of the UK CF Gene Therapy Consortium's strategy group
  • Leadership of Phase IIb clinical trial of nonviral gene therapy for cystic fibrosis
  • Development of lentiviral gene therapy for cystic fibrosis in preparation for a Phase I nasal trial within the next 2-3 years

Neil Carragher (Chair)

  • High-content (image-based) phenotypic screening
  • Cell Pharmacology/Mechanism-of-Action characterisation
  • Biomarker discovery
  • Novel drug combinations

Helen Colhoun

  • Discovery of genetic, proteomic, metabolomic and lipidomic correlates and predictors of complications in diabetes using biobanks linked to e-health care record data.
  • Epidemiology of diabetes, its complications and treatment using e-health record data
  • Clinical trials of drugs in diabetes

David FitzPatrick

  • Genetic diagnostics
  • Human genomic analysis
  • NHS partnerships

Liz Patton

  • Preclinical cancer studies
  • Melanoma
  • Chemical biology
  • Zebrafish models

Andrew McBride

  • Support CMVM research leaders in developing translational projects
  • Provide guidance on available translational funding pathways
  • Provide project management and scientific expertise on funded projects
  • Facilitate interactions between researchers, BD teams and external CROs to foster a translational research community within CMVM

Andrea Taylor

  • Point contact for academics and industry for translational and industrial development at Institute of Genetics and Cancer
  • Academic, industrial and translational expertise in the medicine, biotech and pharma sector
  • EI supports end to end commercial development
  • Business development, industrial collaboration, technology transfer (including patents), spin outs & consultancy

Asier Unciti-Broceta

  • Medicinal Chemistry and Drug Discovery
  • Development of targeted inhibitors and prodrug strategies
  • Patents, spin-out company formation and technology licensing

Helen Nickerson

  • Support development and implementation of  MRC Human Genetics Unit and Institute of Genetics and Cancer Translational Strategy
  • Communication of translational strategy and opportunities to internal and external stakeholders